Molecular Partners AG American Depositary Shares (MOLN)

Molecular Partners reported positive data from an ongoing Phase 1/2a trial of its tetraspecific T-cell engager MP0533 in relapsed/refractory acute myeloid leukemia (AML). The data showed a 30% response rate in the latest cohort, with one patient maintaining a response beyond 6 months. The company plans to further optimize the dosing regimen to maximize the therapeutic benefit of MP0533.

Get the latest financial updates and insights with Wall Street Breakfast's daily podcast available on Seeking Alpha, iTunes, and Spotify.

Upgrades According to Argus Research, the prior rating for AstraZeneca PLC (NASDAQ:AZN) was changed from Hold to Buy. For the second quarter, AstraZeneca had an EPS of $0.86, compared to year-ago quarter EPS of $0.45. At the moment, the stock has a 52-week-high of $71.70 and a 52-week-low of $55.50. AstraZeneca closed at $66.32 at the end of the last trading period. According to RBC Capital, the prior rating for The Toronto-Dominion Bank (NYSE:TD) was changed from Sector Perform to Outperform. In the third quarter, Toronto-Dominion Bank showed an EPS of $1.62, compared to $1.60 from the year-ago quarter. At the moment, the stock has a 52-week-high of $86.02 and a 52-week-low of $58.64. Toronto-Dominion Bank closed at $66.60 at the end of the last trading period. For Apple Hospitality REIT Inc (NYSE:APLE), Wells Fargo upgraded the previous rating of Underweight to Equal-Weight. In the second quarter, Apple Hospitality REIT showed an EPS of $0.48, compared to $0.30 from the year-ago quarter. The stock has a 52-week-high of $18.69 and a 52-week-low of $14.29. At the end of the last trading period, Apple Hospitality REIT closed at $16.34. For Park Hotels & Resorts Inc (NYSE:PK), Wells Fargo upgraded the previous rating of Equal-Weight to Overweight. For the second quarter, Park Hotels & Resorts had an EPS of $0.61, compared to year-ago quarter EPS of $0.16. The stock has a 52-week-high of $20.57 and a 52-week-low of $12.90. At the end of the last trading period, Park Hotels & Resorts closed at $14.22. For Host Hotels & Resorts Inc (NASDAQ:HST), Wells Fargo upgraded the previous rating of Equal-Weight to Overweight. In the second quarter, Host Hotels & Resorts showed an EPS of $0.58, compared to $0.12 from the year-ago quarter. The current stock performance of Host Hotels & Resorts shows a 52-week-high of $21.63 and a 52-week-low of $15.10. Moreover, at the end of the last trading period, the closing price was at $18.24. For Calithera Biosciences Inc (NASDAQ:CALA), HC Wainwright & Co. upgraded the previous rating of Neutral to Buy. In the second quarter, Calithera Biosciences showed an EPS of $1.59, compared to $3.80 from the year-ago quarter. The current stock performance of Calithera Biosciences shows a 52-week-high of $5.10 and a 52-week-low of $0.14. Moreover, at the end of the last trading period, the closing price was at $3.27. According to Piper Sandler, the prior rating for Envista Holdings Corp (NYSE:NVST) was changed from Neutral to Overweight. Envista Holdings earned $0.48 in the second quarter, compared to $0.53 in the year-ago quarter. At the moment, the stock has a 52-week-high of $52.03 and a 52-week-low of $35.24. Envista Holdings closed at $36.60 at the end of the last trading period. See all analyst ratings upgrades. Downgrades For Jowell Global Ltd (NASDAQ:JWEL), TD Securities downgraded the previous rating of Buy to Action List Buy. NoneThe stock has a 52-week-high of $25.78 and a 52-week-low of $0.96. At the end of the last trading period, Jowell Global closed at $1.23. Consumer Edge Research downgraded the previous rating for The Hain Celestial Group Inc (NASDAQ:HAIN) from Overweight to Equal-Weight. For the fourth quarter, Hain Celestial Group had an EPS of $0.08, compared to year-ago quarter EPS of $0.39. The stock has a 52-week-high of $43.53 and a 52-week-low of $21.20. At the end of the last trading period, Hain Celestial Group closed at $21.28. According to JMP Securities, the prior rating for Avalara Inc (NYSE:AVLR) was changed from Market Outperform to Market Perform. Avalara earned $0.02 in the second quarter, compared to $0.02 in the year-ago quarter. The stock has a 52-week-high of $129.34 and a 52-week-low of $66.39. At the end of the last trading period, Avalara closed ...Full story available on Benzinga.com

MOLN earnings call for the period ending December 31, 2021.

Regulatory and other pipeline updates from Biogen (BIIB) and AMGN are among a few key highlights from the biotech sector during the past week.